Lindsey Enewold1, Elad Sharon2, Anish Thomas2. 1. National Cancer Institute, Bethesda, MD, United States. Electronic address: lindsey.enewold@nih.gov. 2. National Cancer Institute, Bethesda, MD, United States.
Abstract
BACKGROUND: Mesothelioma is a rare malignancy that is associated with poor survival. This study aimed to describe the patterns of care and subsequent survival among malignant mesothelioma patients in the United States, while adjusting for patient demographics and comorbidities. METHODS: A random sample of patients diagnosed with histologically confirmed mesothelioma in 2011, as reported to the National Cancer Institute's Surveillance Epidemiology and End Results program, were included. Logistic regression and Cox proportional hazard regression were utilized to identify factors associated with receipt of therapy and all-cause mortality, respectively, among patients with pleural mesothelioma. RESULTS: This study included 389 patients with pleural mesothelioma and 53 patients with non-pleural mesothelioma. Almost a third (29.3%) of the pleural patients and 21.5% of the non-pleural patients received no therapy. Additionally, approximately 60% of both patient groups received systemic therapy. Among pleural mesothelioma patients, receipt of therapy was less likely among older patients. Median survival was 9 months among the pleural patients and 18 months among the non-pleural patients. Receipt of either surgery or systemic therapy and particularly the combination of these two modalities was associated with better all-cause survival. Additionally, among pleural mesothelioma patients, younger age and lower socioeconomic status were found to be associated with better all-cause survival. Comorbidity score was not found to be associated with receipt of treatment nor was it independently associated with survival among pleural mesothelioma patients. CONCLUSION: These findings indicate the need for efforts to ensure equitable application of currently available therapies to all patients. Published by Elsevier B.V.
BACKGROUND: Mesothelioma is a rare malignancy that is associated with poor survival. This study aimed to describe the patterns of care and subsequent survival among malignant mesothelioma patients in the United States, while adjusting for patient demographics and comorbidities. METHODS: A random sample of patients diagnosed with histologically confirmed mesothelioma in 2011, as reported to the National Cancer Institute's Surveillance Epidemiology and End Results program, were included. Logistic regression and Cox proportional hazard regression were utilized to identify factors associated with receipt of therapy and all-cause mortality, respectively, among patients with pleural mesothelioma. RESULTS: This study included 389 patients with pleural mesothelioma and 53 patients with non-pleural mesothelioma. Almost a third (29.3%) of the pleural patients and 21.5% of the non-pleural patients received no therapy. Additionally, approximately 60% of both patient groups received systemic therapy. Among pleural mesothelioma patients, receipt of therapy was less likely among older patients. Median survival was 9 months among the pleural patients and 18 months among the non-pleural patients. Receipt of either surgery or systemic therapy and particularly the combination of these two modalities was associated with better all-cause survival. Additionally, among pleural mesothelioma patients, younger age and lower socioeconomic status were found to be associated with better all-cause survival. Comorbidity score was not found to be associated with receipt of treatment nor was it independently associated with survival among pleural mesothelioma patients. CONCLUSION: These findings indicate the need for efforts to ensure equitable application of currently available therapies to all patients. Published by Elsevier B.V.
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: A G Pallis; C Fortpied; U Wedding; M C Van Nes; B Penninckx; A Ring; D Lacombe; S Monfardini; P Scalliet; H Wildiers Journal: Eur J Cancer Date: 2010-03-12 Impact factor: 9.162
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316
Authors: Jennifer L Beebe-Dimmer; Jon P Fryzek; Cecilia L Yee; Tapashi B Dalvi; David H Garabrant; Ann G Schwartz; Shirish Gadgeel Journal: Clin Epidemiol Date: 2016-10-26 Impact factor: 4.790
Authors: G L Ceresoli; F Grosso; P A Zucali; M Mencoboni; G Pasello; C Ripa; D Degiovanni; M Simonelli; A Bruzzone; C Dipietrantonj; E Piccolini; G D Beretta; A G Favaretto; L Giordano; A Santoro; M Botta Journal: Br J Cancer Date: 2014-06-10 Impact factor: 7.640
Authors: Sara V Soldera; John Kavanagh; Melania Pintilie; Natasha B Leighl; Marc de Perrot; John Cho; Andrew Hope; Ronald Feld; Penelope A Bradbury Journal: Oncologist Date: 2018-11-26
Authors: Yang Su; Xin Zhang; Scott Bidlingmaier; Christopher R Behrens; Nam-Kyung Lee; Bin Liu Journal: Cancer Res Date: 2020-08-31 Impact factor: 12.701
Authors: Glaucia N M Hajj; Carolina H Cavarson; Clóvis Antônio Lopes Pinto; Gabriela Venturi; João R Navarro; Vladmir C Cordeiro de Lima Journal: J Bras Pneumol Date: 2021-12-13 Impact factor: 2.800
Authors: Mark D Danese; Melinda Daumont; Esmond Nwokeji; Michelle Gleeson; John R Penrod; Deborah Lubeck Journal: Cancer Rep (Hoboken) Date: 2021-10-26